The effectiveness of new hormone therapy treatments on progression-free survival of patients with HR+/HER2- metastatic breast cancer: a systematic review
DOI:
https://doi.org/10.33448/rsd-v10i14.21940Keywords:
Breast cancer; Hormone therapy; Survival; Cyclin-dependent kinase inhibitors.Abstract
Objective: Breast cancer is the most prevalent cancer that affects women, second only to non-melanoma skin cancers. Cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors are the latest hormone therapy option for patients with HR+/HER2- metastatic breast cancer. Thus, the present study seeks to understand the effectiveness of new hormone therapy treatments in the progression-free survival of patients with HR+/HER2- metastatic breast cancer. Methodology: A systematic review of literature was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) model, through database searches on Pubmed, Lilacs, BioOne, The Cochrane Library, Scielo, IBECS and Medline. Results: The combination of CDK 4/6 inhibitors with aromatase inhibitors has demonstrated better results regarding progression-free survival for first-line treatment of HR+/HER2- metastatic breast cancer, being adopted by the main guidelines of American and European societies of Oncology. The best average progression-free survival was 28.2 months, achieved with the abemaciclib plus letrozole combination. As regards overall survival, the best time obtained was 54.1 months with fulvestrant monotherapy. Conclusion: CDK 4/6 inhibitors are novelty with regard to the treatment of HR+/HER2- metastatic breast cancer, having great results for progression-free survival when combined with aromatase inhibitors or fulvestrant.
References
Battisti, N., De Glas, N., Sedrak, M. S., Loh, K. P., Liposits, G., Soto-Perez-de-Celis, E., Krok-Schoen, J. L., Menjak, I. B., & Ring, A. (2018). Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Ther. Adv. Med. Oncol., 10, Artigo 1758835918809610.
Brufsky, A., Liu, X., Li, B., McRoy, L., & Layman, R. M. (2021). Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. Target Oncol., 16(5), 601-611.
Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. (2015). Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J. Clin. Oncol., 33(32), 3781-3787.
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C., Huang, X., Kim, S. T., Randolph, S., & Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol., 16(1), 25-35.
Galvão, T. F., Pansani, T. S. A., & Harrad, D. (2015) Principais itens para relatar Revisões sistemática e Meta-análises: a recomendação PRISMA. Epidemiol. Serv. Saúde, 24(2), 335-342.
García-Trevijano Cabetas, M., Lucena Martínez, P., Jiménez Nácher, I., Díaz Almirón, M., Zamora Auñón, P., & Herrero Ambrosio, A. (2021). Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer. Int. J. Clin. Pharm., 43(4), 893-899.
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S. C., Manso, L., Freedman, O. C., Jaliffe, G. G., Forrester, T., Frenzel, M., Barriga, S., Smith, I. C., Bourayou, N., & Di Leo, A. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J. Clin. Oncol., 35(32), 3638-3646.
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., Senn, H. J., & Panel members. (2011). Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology, 22(8), 1736-1747.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., & Yap, Y. S. (2016). Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N. Engl. J. Med., 375, 1738-1748.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2019a). A situação do câncer de mama no Brasil: síntese de dados dos sistemas de informação. INCA.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2019b). Estimativa 2020: incidência de câncer no Brasil. INCA.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2021a). Atlas da mortalidade. https://www.inca.gov.br/MortalidadeWeb/pages/Modelo01/consultar.xhtml;jsessionid=D74E682A80B15156B5E577DD6522DEE1#panelResultado.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2021b). Câncer de mama - versão para Profissionais de Saúde. https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama/profissional-de-saude.
Johnston, S., Martin, M., Di Leo, A., Im, S. A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., Toi, M., Iwata, H., & Goetz, M. P. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer, 5, Artigo 5.
Kovač, A., Matos, E., Kuhar, C. G., Čakš, M., Ovčariček, T., Mencinger, M., Humar, M., & Borštnar, S. (2020). Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting. Cancer Treat. Res. Commun., 25, Artigo 100201.
Lei, W., Li, H., Song, G., Zhang, R., Ran, R., Yan, Y., Di, L., & Jiang, H. (2020). Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. J. Cancer, 11(22), 6612-6622.
Li, J., Huo, X., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., & Zhao, J. (2020). Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw. Open, 3(10), Artigo e2020312.
Mycock, K., Zhan, L., Taylor-Stokes, G., Milligan, G., & Mitra, D. (2021). Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study. Curr. Oncol., 28(1), 678-688.
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Lu, Y., Haddad, N., Hurt. K. C., & Sledge, G. W., Jr. (2021). Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Res., 23, Artigo 87.
O’Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., Hart, L. L., Villanueva, C., Jakobsen, E., Beck, J. T., Lindquist, D., Souami, F., Mondal, S., Germa, C., & Hortobagyi, G. N. (2018). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res. Treat., 168(1), 127-134.
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Di Gioia, G., Di Lauro, V., Rella, F. D., Fusco, G., Iodice, G., Nuzzo, F., Pacilio, C., Pensabene, M., & De Laurentiis, M. (2020). Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int. J. Mol. Sci., 21(17), Artigo 6400.
Portaria conjunta n. 19, de 3 de julho de 2018. (2018). Aprova as Diretrizes Diagnósticas e Terapêuticas do Carcinoma de Mama. Brasília. Secretaria de Atenção à Saúde e Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Robertson, J. F., Lindemann, J. P., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Emerson, L., Dean, A., & Ellis, M. J. (2012). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res. Treat., 136(2), 503-511.
Robertson, J., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K. L., Philco-Salas, M. J., Ruiz-Borrego, M., Shao, Z., Noguchi, S., Rowbottom, J., Stuart, M., Grinsted, L. M., Fazal, M., & Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005.
Rugo, H. S., Finn, R. S, Gelmon, K., Joy, A. A., Harbeck, N., Castrellon, A., Mukai, H., Walshe, J. M., Mori, A., Gauthier, E., Lu, D. R., Bananis, E., Martin, M., & Diéras, V. (2020). Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin. Breast Cancer, 20(2), e173-e180.
Seki, H., Sakurai, T., Maeda, Y., Oki, N., Aoyama, M., Yamaguchi, R., Tokuda, T., Kaburagi, T., Okumura, T., Karahashi, T., Nakajima, K., Higeta, K., & Shimizu, K. (2019). Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer. In Vivo, 33(6), 2037-2044.
Skinner, K. E., Olufade, T., Walker, M. S., & Schwartzberg, L. S. (2020). Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer. Breast J., 26(2), 112-119.
Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E. M., Conte, P., Lu, Y., Barriga, S., Hurt, K., Frenzel, M., Johnston, S., & Llombart-Cussac, A. (2020). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol., 6(1), 116-124.
Sociedade Brasileira de Oncologia Clínica. (2021). Mama: doença metastática. SBOC.
Sonke, G. S., Hart, L. L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E., Alba, E., Wist, E., Favret, A. M., Bachelot, T., Hegg, R., Wheatley-Prince, P., Souami, F., Sutradhar, S., Miller, M., Germa, C., & Burris, H. A. (2018). Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res. Treat., 167(3), 659-669.
Toi, M., Inoue, K., Masuda, N., Iwata, H., Sohn, J., Hae Park, I., Im, S. A., Chen, S. C., Enatsu, S., Turner, P. K., André, V., Hardebeck, M. C., Sakaguchi, S., Goetz, M. P., & Sledge, G. W., Jr. (2021). Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci., 112(6), 2381-2392.
Waller, J., Mitra, D., Mycock, K., Taylor-Stokes, G., Milligan, G., Zhan, L., & Iyer, S. (2019). Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. J. Glob. Oncol., 5, Artigo JGO1800239.
Wilkie, J., Schickli, M. A., Berger, M. J., Lustberg, M., Reinbolt, R., Noonan, A., Ramaswamy, B., Sardesai, S., VanDeusen, J., Wesolowski, R., Williams, N., Stover, D. G., Li, J., & Vargo, C. A. (2020). Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. Clin. Breast Cancer, 20(1), 33-40.
Yardley, D. A., Hart, L., Favret, A., Blau, S., Diab, S., Richards, D., Sparano, J., Beck, J. T., Richards, P., Ward, P., Ramaswamy, B., Tsai, M., Blackwell, K., Pluard, T., Tolaney, S. M., Esteva, F. J., Truica, C. I., Alemany, C., Volas-Redd, G., Shtivelband, M., Purkayastha, D., Dalal, A. A., Miller, M., & Hortobagyi, G. N. (2019). Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. Clin. Breast Cancer, 19(4), 268-277.e1.
Zhang, Q. Y., Sun, T., Yin, Y. M., Li, H. P., Yan, M., Tong, Z. S., Oppermann, C. P., Liu, Y. P., Costa, R., Li, M., Cheng, Y., Ouyang, Q. C., Chen, X., Liao, N., Wu, X. H., Wang, X. J., Feng, J. F., Hegg, R., Kanakasetty, G. B., Coccia-Portugal, M. A., Han, R. B., Lu, Y., Chi, H. D., Jiang, Z. F., & Hu, X. C. (2020). MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther. Adv. Med. Oncol., 12, Artigo 1758835920963925.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Lucas Rodrigues da Silva; Nathália de Lima Queiroz; Marina dos Santos Menezes; Janaina Alves de Carvalho; Areta Agostinho Rodrigues de Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
